AppLovin stock sinks after short-seller report alleges money laundering; company calls claims “nonsensical”
21 January 2026
1 min read

AppLovin stock sinks after short-seller report alleges money laundering; company calls claims “nonsensical”

New York, Jan 21, 2026, 17:30 EST — After-hours

  • AppLovin shares dropped nearly 6% on Wednesday, pushing down a decline that started the previous day.
  • Short-seller CapitalWatch flagged possible compliance issues and financial crimes connected to shareholder funding and advertising tools.
  • AppLovin dismissed the allegations, stating it has no control over who trades its shares.

Shares of AppLovin Corp (APP.O) dropped 5.9% on Wednesday, closing near $532.56 in late trading. The decline came after the company denied claims made in a short-seller report linking the mobile ad firm to money laundering.

The timing of these claims is tricky for AppLovin. Its stock has surged, drawing a lot of attention, and accusations related to anti-money-laundering controls often escalate beyond valuation issues into serious governance concerns.

They also pose a practical question for investors: will any regulator, exchange, bank, or key business partner decide the accusations merit further scrutiny, despite the company’s denials?

CapitalWatch, calling its work a forensic investigation and fund analysis, flagged “systemic compliance risks.” It claimed certain networks might have skirted global anti-money laundering rules to funnel money into U.S. markets via AppLovin-linked holdings. (A short seller is an investor who bets a stock will fall.) (Source: 1 )

AppLovin pushed back against the allegations in an emailed statement to Investing.com, labeling the report “false, misleading, and nonsensical.” The company said it “categorically” denies the claims concerning its ownership structure and international operations. (Source: 2 )

The short report flagged AppLovin’s ad tech, including its AXON algorithm, suggesting some features might be exploited to mask illicit money flows, according to Investing.com. AppLovin pushed back, saying it conducts “Know Your Customer” checks and tax verifications to vet counterparties. The company dismissed the report’s claims as economically unrealistic. (Source: 2 )

Piper Sandler’s James Callahan stuck to his bullish view on Jan. 20, stating the report “provides little evidence to support the claims.” He kept his Overweight rating and $800 price target, TheFly noted. (Source: 3 )

TipRanks flagged Callahan’s Jan. 20 reiteration under the same “look past” note headline in its analyst-forecast feed for the stock. (Source: 4 )

Shares opened Wednesday at $555.01 and fluctuated between $530.12 and $565.15 throughout the day.

The next move hinges less on today’s tape and more on how the allegations develop. Investors remain in the dark about whether any authority will step in, if CapitalWatch will release further reports, or if counterparties will raise concerns that don’t make the headlines.

AppLovin plans to release its fourth-quarter and full-year 2025 earnings on Feb. 11, following the U.S. market close. The company will hold a webcast at 5 p.m. ET that day. For now, this earnings announcement is the key date for the stock. (Source: 5 )

Stock Market Today

Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

8 February 2026
New York, Feb 7, 2026, 20:34 (EST) — Market closed. Astera Labs, Inc. shares surged 18.9% on Friday to close at $169.85, after ending the prior session at $142.82. The stock traded between $151.42 and $170.01, with about 7.3 million shares changing hands. 1 With U.S. markets shut for the weekend, the move leaves the Nasdaq-listed chip-connectivity firm in focus heading into Monday’s open. Attention now shifts to its quarterly report due next week, a key check on demand for parts that sit inside AI data centers. Astera Labs makes connectivity chips and software that help move data inside servers
Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

8 February 2026
Sungrow closed at 144.50 yuan, down 1.03%, after stating it has no plans in the commercial space sector. Mainland China trading resumes Monday, with Spring Festival closures set for Feb. 15–23. Major funds were net sellers of 5.46 billion yuan on Feb. 6. The Shenzhen-listed solar firm remains under scrutiny as investors await further filings before the holiday.
MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

8 February 2026
Monolithic Power Systems shares surged 6.4% to $1,229.82 Friday, hitting a new 52-week high after raising its dividend to $2.00 and forecasting first-quarter revenue of $770 million to $790 million. CEO Michael Hsing filed a Rule 144 notice for 3,082 shares. CFO Bernie Blegen will retire after the 2025 annual report, with Rob Dean named interim CFO. Fourth-quarter revenue rose 20.8% to $751.2 million.
Microchip Technology stock price: MCHP heads into Monday after earnings outlook and mixed analyst calls

Microchip Technology stock price: MCHP heads into Monday after earnings outlook and mixed analyst calls

8 February 2026
Microchip Technology shares fell 2.6% to $76.01 Friday after its outlook and analyst reactions disappointed some investors. The company reported fiscal Q3 net sales up 15.6% to $1.186 billion and guided March-quarter sales to $1.24–$1.28 billion. A global memory shortage has disrupted orders, and analysts remain split on recovery prospects. BlackRock disclosed a 10% stake as of Jan. 31.
Walmart stock price ticks up after PhonePe IPO approval — what WMT investors watch next
Previous Story

Walmart stock price ticks up after PhonePe IPO approval — what WMT investors watch next

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set
Next Story

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Go toTop